Loading…

5PSQ-137 When is a drug interaction not a drug interaction? Comparison of drug-drug interactions-checking databases between the UK and USA

BackgroundThe drug-drug interaction (DDI)-checking function of an electronic medical record (EMR) is helpful but is also a distraction, firing too many warnings and triggering alert fatigue. Anecdotally, hospital staff ignore warnings in over 50% of cases. Additionally, there are a number of commonl...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A265-A265
Main Authors: Junaid, E, Hermes-DeSantis, ER, Bhalla, N, Cadman, B, Eggleton, A
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundThe drug-drug interaction (DDI)-checking function of an electronic medical record (EMR) is helpful but is also a distraction, firing too many warnings and triggering alert fatigue. Anecdotally, hospital staff ignore warnings in over 50% of cases. Additionally, there are a number of commonly used DDI-checking databases available.PurposeWhat is the concordance of DDI databases when evaluating identified high-risk interactions alerts on an EMR system? Can the number of alerts be safely downgraded to alert fatigue?Material and methodsComparison of DDI-checking databases: Stockley’s Drug Interactions in the UK and Lexicomp (Lexi), Micromedex (MDX) and Facts and Comparison (Facts) in the USA.Based on their review, 477 interactions were recommended to be downgraded to moderate risk. These 477 interactions were further evaluated by a USA-based senior pharmacist utilising the DDI-checking databases of Lexi, MDX and Facts to identify the severity of the interaction. The agreement across all three databases, as well as between each database, was analysed. Descriptive statistics analysed the difference between the ratings and agreement in each database with the Chi square and an alpha set to 0.01.ResultsOf the 477 interactions evaluated, Lexi, MDX and Facts, agreed on the rating only 17.8% (85/477) of the time. Of these 85 interactions, 68 (80%) were no interaction/none reported, 2% (2/85) were considered a moderate interaction and 18% (15/85) were considered a major interaction. However, for moderate interaction (4% versus 19%, p
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2019-eahpconf.570